Andreas Loew

Founder and Chief Executive Officer

Andreas founded Elstar Therapeutics after an outstanding career of scientific discovery and drug development leadership. For over 14 years, Andreas served in positions of increasing responsibility at Abbott Bioresearch Center (ABC) and at the Novartis Institute for Biomedical Research (NIBR). As the executive director of NIBR Biologics, New Technologies, he managed a global research laboratory focused on the design, selection, and validation of protein therapeutics. Among his many contributions, he implemented a discovery platform for chimeric antigen receptors (CAR) for cancer immunotherapy, designed multi-functional therapeutic proteins and antibodies, and directed R&D efforts for nanoparticle delivery of mRNA. In recognition of his scientific achievements he received the Novartis VIVA (Vision, Innovation, Value, Achievement) award as one of the company’s leading scientists in 2014.

He is named as an inventor on more than 180 patents in fields that include engineered CAR-T cells, bispecific antibodies, therapeutic proteins, non-antibody protein scaffolds, yeast display, RNA guided gene editing technologies, and small molecule kinase inhibitors.

Andreas earned his Ph.D. in Biochemistry at the University of Bayreuth, Germany, and has held research positions at the University of Texas, University of Illinois, and Birkbeck College, London.


Peter Williams

Chief Business Officer

Peter has over twenty years of experience in business development, deal negotiation, technology in- and out-licensing and relationship management in the biotechnology sector.  He has considerable expertise in technology and product partnering, particularly in oncology and previously served as Senior Director, Business Development at Millennium Pharmaceuticals, Senior Director, Business Development at Alnylam Pharmaceuticals and, most recently, as Vice President of Business Development at ImmunogGen, Inc.

Peter earned his MSc in Management at Imperial College, University of London and BSc in Biology at the University of Sussex.


Elizabeth Quackenbush

Head of Translational Medicine

Elizabeth is a Physician Scientist who has more than 19 years of experience in preclinical development and clinical research across a range of disease areas, including cardiovascular-, oncologic-, and inflammatory-based indications. Most recently, she was a Translational Medicine Leader for four years in the early oncology group at Roche (New York City), where she served as an expert scientist for multiple compounds being assessed in patients with solid tumors and hematologic malignancies. Prior to her tenure at Roche, Elizabeth held positions in clinical development at Celldex Therapeutics and at Agennix AG, where she designed and led preclinical projects to better understand the mechanism of action of the lead asset. Elizabeth started her career in industry at Merck and Co., where she established the first in vivo imaging group and helped progress several immunology programs, as a scientist in the in vivo pharmacology division and as a medical director in late stage clinical development. Prior to joining Merck, she was an attending physician in clinical genetics at Boston Children’s Hospital, where she completed her fellowship training.

Elizabeth received her Ph.D.  in Immunology from the University of Toronto and did post-doctoral work at the Dana-Farber Cancer Institute, prior to obtaining her medical degree at the University of Toronto. Her internal medicine training was completed at St. Michael’s Hospital in Toronto and at the Beth Israel Hospital in Boston, MA.


Seng-Lai (Thomas) Tan

Vice President, Immunology

Thomas has over 18 years of drug discovery and development experience in both small and large molecule therapeutic modalities, including multi-specific antibodies and stapled peptides. Prior to joining Elstar Therapeutics, Thomas has led cross-functional and global project teams and external alliances spanning different therapeutic areas including oncology, autoimmunity, and infectious diseases at Eli Lilly and Company, Amgen, Roche, and Merck Serono. More recently, he was a Senior Director of Immunology at FORMA Therapeutics, where he built discovery teams and platforms from the ground up and helped progress several discovery programs to lead and development candidate stage.

Thomas received his Ph.D.  in Microbiology and Immunology from the University of Washington School of Medicine, Seattle, where he also did his postdoctoral training. He has over 60 publications and book editorials and has held adjunct faculty position at the Indiana University School of Medicine, Indianapolis.


Sangeetha Palakurthi

Vice President, In Vivo Pharmacology

Sangeetha joined Elstar Therapeutics with extensive oncology drug discovery and preclinical development experience within both pharmaceutical and academic settings. Most recently, she served as the head of the Cancer Biology and Pharmacology team at the Belfer Center for Applied Cancer Science at the  Dana-Farber Cancer Institute. Her responsibilities there included design and execution of a portfolio of industry and academic investigator sponsored translational pharmacology projects of targeted agents and immunotherapies to enable better clinical trial design decisions. Prior to that, Sangeetha led and supported oncology drug discovery programs from target identification to candidate drug nomination at AstraZeneca. Her research included design of strategies and execution of rationale-driven “proof of concept” studies to guide translation of right drugs to the right patients.

Sangeetha received her Ph.D. in Biochemistry from the Osmania University in India and worked as a Scientist at Dr. Reddy’s Laboratories prior to her postdoctoral fellowship at Harvard Medical School.

bio pic

Madan Katragadda

Vice President, Antibody Discovery and Protein Engineering

Madan Katragadda heads Antibody Discovery and Protein Engineering group, which is responsible for, discovering, designing and delivering Elstar’s biotherapeutic candidates with optimal biophysical and manufacturable properties. He has more than 15 years of experience discovering and developing a wide range of biotherapeutic modalities spanning peptides, fusion proteins, Antibody-drug-conjugates and multi-specific Antibodies. His first foray into biotherapeutics started with discovery of peptide-based complement inhibitors during his postdoc tenure at the University of Pennsylvania. His work led to out-licensing of an anti-C3 peptide to Apellis pharmaceuticals who is currently testing it in several inflammatory diseases in Phase II.

Prior to joining Elstar, Madan held positions with increasing responsibility at Pfizer, where he led an Antibody Engineering group, built cross-functional teams to deliver on innovative ideas and new technology platforms and managed several biotherapeutic projects through internal and external collaborations. He delivered several biotherapeutic candidates to treat Inflammatory and Oncology indications for preclinical/clinical development. His work at the University of Pennsylvania and Pfizer resulted in several patents and publications.

Madan holds a Ph.D. in Biochemistry from the University of Connecticut and completed his postdoctoral training at the University of Pennsylvania.


Patricia Deware

Vice President, Finance

Patricia has over 25 years of accounting and finance leadership experience in companies ranging in size from early stage, venture-backed to Fortune 500 companies. She has had roles in financial management and analysis, public accounting, and strategic financial consulting across multiple industries including consumer products, financial services, and life sciences. Prior to joining Elstar, Pat was the Chief Financial Officer at Selventa, an early-stage analytics and molecular diagnostics company, where she oversaw finance and operations and provided guidance on financial planning, cash flow management, and capital structure and financings. Previously, she provided financial leadership to other biotech and medical device companies including Syntimmune, Codiak Biosciences, and Diagnostic Vision Corporation. Pat has also held senior management roles at Fidelity Investments and Avery Dennison.